Antibody-drug conjugates

 

From feasibility study to in vitro and in vivo evaluation of ADC

Progresses in genetic engineering and immunology have paved the way for new types of monoclonal antibodies, at the first rank of which are immunoconjugates or ADC (Antibody-Drug Conjugates).

In practice, a specific antibody against tumor is coupled to an active substance (toxin, medicine, enzyme or even radioactive isotope). Once the antibody has reached its destination, this substance is then released in the heart of the tumor cells.


Mi-mAbs offer covers feasibility studies of the immunoconjugate in assessing its effectiveness in vitro and in tumor models.

Antibodies from the platform or provided by the partner can be coupled with clinically validated drugs (including the family of the auristatin toxins) using conventional (coupling on cysteine) or site-specific methods (enzymatic conjugation with particular linkers).

Mi-mAbs relies on mass spectrometry technology to assess the ratio of antibody/toxin of the immunoconjugates and testing their effectiveness: first, in vitro, on cell lines then, in vivo, on syngeneic or xenogeneic tumor models.

Pharmacokinetic of ADC in vivo can be assessed through ELISA and mass spectrometry to evaluate both antibody concentrations and drug antibody ratio after injection.

Mi-mAbs has access to the technology of coupling developed by Innate Pharma for research purposes. Tested in various pre-clinical models, this technology allows rapid generation of homogeneous antibodies conjugated with an exact antibody/toxin ratio (2:1 or 4:1).